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ABSTR ACT: Colorectal cancer (CRC) is the third most common malignancy and the second most common cause of cancer death worldwide. Early 
detection of CRC can improve patient survival rates; thus, the identification of noninvasive diagnostic markers is urgently needed. MicroRNAs (miRNAs) 
have extensive potential to diagnose several diseases, including cancer. In this study, we compared the expression pattern of miRNAs from plasma and stool 
samples of patients with early stages of CRC (I, II) with that of healthy subjects. We performed miRNA profiling using microarrays on plasma and stool 
samples of eight patients with CRC and four healthy subjects. Seven miRNAs were found to be underexpressed in both plasma and stool samples of patients 
with CRC versus healthy subjects. Then, we aimed to verify two out of these seven differentially expressed miRNAs (let-7a-5p and let-7f-5p) by quantitative 
reverse transcriptase polymerase chain reaction on a larger set of plasma and stool samples of 51 patients with CRC and 26 healthy subjects. We confirmed 
the results of microarray analysis since their expression was significantly lower in stool and plasma samples of patients with CRC. Moreover, receiver oper-
ating characteristic curve analysis demonstrated that fecal let-7f expression levels have significant sensitivity and specificity to distinguish between patients 
with CRC and healthy subjects. In conclusion, if the results are confirmed in larger series of patients, underexpressed let-7a-5p and let-7f-5p miRNAs in 
both plasma and stool samples of patients with CRC may serve potentially as noninvasive molecular biomarkers for the early detection of CRC.
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Introduction
Despite the existence of screening, preventive, and therapeutic 
strategies, colorectal cancer (CRC) is still the third most 
common malignancy and the second most common cause of 
cancer death, with an estimated 1.2 million new cases and 
more than 600,000 deaths annually, worldwide.1–3 Initia-
tion and progression of CRC is a slow process lasting several 
years, and it usually begins with cryptic lesions and gradu-
ally develops to adenoma and finally to malignant carcinoma, 
with the potential for invasion and metastasis.4 Early detec-
tion of this neoplasm is critical because patient survival rate 
and response to treatment are strongly associated with tumor 
stage and disease progression at the time of diagnosis. It has 
been estimated that almost 95% of patients would be cured 
if diagnosis was made at an early or precursor lesion stage.5 
Therefore, new, accurate, and reliable diagnostic methods that 
improve early detection and monitoring of CRC are necessary.
MicroRNAs (miRNAs) are short (18–24 nucleotides), 
highly conserved noncoding endogenous RNAs, which regu-
late gene expression posttranscriptionally.6,7 Numerous studies 
have shown that the alteration of miRNAs expression is 
involved in the pathogenesis of several types of cancers, such 
as CRC, by regulating the expression of tumor suppressors 
and oncogenes.8,9 Differential expression of miRNAs has also 
been detected in serum, plasma,10–15 and stool of patients with 
CRC.16–22
In this study, we compared the expression pattern of 
miRNAs in paired plasma and stool samples of patients with 
early stages (I, II) of CRC and of neoplasm-free individuals 
as controls.
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Materials and Methods
Patients. In this study, a total of 51 patients with CRC 
and 26 healthy controls were enrolled for the evaluation of 
miRNAs from plasma and stool samples at the Digestive 
Disease Research Institute, Shariati Hospital, Tehran, Iran, 
from August 2011 to October 2012. Patients with CRC and 
healthy controls had similar age (P-value =  0.776, indepen-
dent samples t-test) and gender (P-value = 0.567, chi-square 
test) distribution. Clinical and demographical data of partici-
pants are presented in Table 1.
Plasma and stool samples were collected from 51 newly diag-
nosed, pathologically confirmed patients with early stages (I, II) 
of CRC before receiving any treatment and from 26 healthy sub-
jects who were free of CRC and colorectal polyps as examined 
by colonoscopy. Tumor was staged according to the tumor node 
metastasis staging system of the Union for International Cancer 
Control guidelines. The patients with a history of concurrent 
malignant diseases were excluded from this study. Plasma and 
stool samples were stored at −80°C until use. Informed con-
sent was obtained from all participants for the use of their blood 
and stool samples in this study. This research complied with the 
principles of the Declaration of Helsinki and was approved by 
the Institutional Review Board of Shariati Hospital.
RNA isolation. Extraction of total RNA, including 
miRNAs, from plasma and stool samples was carried out 
using miRNAeasy Serum/Plasma Kit (Qiagen GmbH) and 
miRNAeasy Mini Kit (Qiagen GmbH), respectively. For 
stool samples, the protocol was slightly modified to increase 
the RNA yield. Briefly, ~100 mg of stool was homogenized 
with 1 mL of RNase-free water and 200 μL of this was lysed 
with QIAzol lysis reagent in a proportion of 1:6. RNA was 
precipitated with chloroform, and the aqueous phase was 
mixed with 1.5 volumes of 100% ethanol.17 The concen-
tration of extracted RNA was measured using the Nano-
Drop-1000 Spectrophotometer (Thermo Fisher Scientific, 
Inc.). Agilent’s Bioanalyzer (Agilent Technologies) was 
used for checking the quality of total RNA with the RNA 
6000 chip and miRNA with the small RNA chip (Agilent 
Technologies).
MicroRNA microarray expression profiling and data 
analysis. Eight paired stool and plasma samples of patients 
with CRC and four paired stool and plasma samples of healthy 
individuals were randomly selected to identify the miRNA 
expression signature. MiRNA profiling was done with Agi-
lent’s miRNA microarray system (V19), containing 2,006 
human miRNAs (Agilent Technologies). RNA labeling and 
hybridization were performed according to Agilent’s protocol 
version 2.4. Briefly, 100 ng of the total RNA was dephosphory-
lated with calf intestinal alkaline phosphatase by incubation 
at 37°C for 30 minutes. In the denaturation step, dimethyl 
sulfoxide (100%) was added to each sample, and after incuba-
tion at 100°C for eight minutes, the samples were immediately 
transferred to an ice–water bath. Then, samples were labeled 
with Cyanine3-pCp by incubation with T4 RNA ligase for 
two hours at 16°C. After labeling, samples were completely 
dried in a vacuum concentrator at 45°C–55°C and resuspended 
in nuclease-free water. The samples were hybridized to array 
active side in Agilent SureHyb Chambers at 55°C for 20 hours. 
The microarrays were then washed with washing buffers 1 and 
2 and scanned on an Agilent’s Microarray Scanner. The infor-
mation of probe features was extracted from the microarray 
scan data using Agilent Feature Extraction Software. Finally, 
the miRNA expression analysis was performed using Gene-
Spring GX Analysis software (Agilent Technologies).
Statistical significance of differential expression between 
the CRC and control groups was determined by t-test. The 
false discovery rate method of Benjamini–Hochberg proce-
dure was used to correct for multiple comparisons. miRNAs 
with a fold-change of 2, and P-values 0.05 were consid-
ered differentially expressed.
Validation of microarray results with quantitative 
reverse transcriptase polymerase chain reaction (qRT-PCR). 
A set of 51 paired plasma and stool samples of CRC patients 
(stage I, n = 12; stage II, n = 39) and 26 paired plasma and stool 
Table 1. Characteristics of patients with CrC and healthy subjects.
CRC PATIENTS HEALTHY SUBJECTS P-VALUEb
age 65.04 yrs ± 9.13 61.04 yrs ± 9.17 0.776
Gender 0.567
male 27 14
Female 24 12
Tnm stagea
i 12 –
ii 39 –
Tumor location
Colon 45 –
rectum 6 –
Notes: aTnm: tumor-node-metastasis staging system according to the Union for international Cancer Control (UiCC) guidelines. bP-value for age was calculated by 
independent sample t-test; P-value for gender was calculated by chi-square test.
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samples of healthy controls (including the patients and healthy 
subjects used for miRNA microarray analysis) were used for 
validation of the miRNA microarray findings by SYBR-Green-
based quantitative reverse transcriptase polymerase chain reac-
tion (qRT-PCR). Two miRNAs, let-7a-5p and let-7f-5p, were 
selected for validation based on miRNA array results and also 
because of the known role of let-7 family of miRNAs in human 
cancer. Reverse transcription of the extracted RNA was per-
formed by the miScript Reverse Transcription Kit (Qiagen 
GmbH), according to the manufacturer’s recommendations. 
Quantification of miRNA was performed using SYBR Green 
miScript PCR system (Qiagen GmbH) on LightCycler v.3.5 
software (Roche Applied Science). Each reaction was per-
formed in a 20 μL volume with 10 ng of template cDNA, and 
all reactions were run in duplicates. RNU6B miScript Primer 
Assay (Qiagen GmbH) was used as an endogenous control for 
normalization of the data. Relative Expression Software Tool 
(REST 2009) was used to evaluate statistically significant 
differences in miRNA expression between the two groups.23 
P-values 0.05 were considered statistically significant.
Results
Plasma and stool miRNA microarray profiling. RNA 
concentrations ranged from 20 to 51 ng/μL and from 62 to 
1,430 ng/μL in plasma and stool samples, respectively. Quality 
of total RNA and miRNA was acceptable to perform subse-
quent miRNAs microarrays and the validation study. Analy-
sis of our array results from comparisons of plasma and stool 
samples of eight patients with CRC versus four healthy sub-
jects using GeneSpring GX software showed several signifi-
cantly differentially expressed miRNAs. At the fold change 
cutoff of 2.0 and P  0.05, q  0.3 results of CRC plasma 
miRNA arrays in comparison with normal samples revealed 
78 significantly downregulated and two significantly upreg-
ulated miRNAs, and for stool samples, our results revealed 
148 significantly  downregulated and two significantly upreg-
ulated miRNAs. All data of microarray results are listed in 
Supplementary Table 1. Interestingly, seven miRNAs were 
downregulated in both plasma and stool specimens of patients 
with CRC compared with those of healthy controls (P  0.05, 
q  0.3; Fig. 1).
Figure 1. Diagramatic representation of the mirnas differentially expressed in plasma and stool of patients with CrC compared to healthy subjects. 
The venn diagram shows 150 differentially expressed mirnas in stool and 80 in plasma compared to healthy individuals. The intersection depicts seven 
mirnas underexpressed in both plasma and stool of patients with CrC, which are shown in detail in a table.
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Figure 2. Plasma let-7a-5p and let-7f-5p expression levels in 51 patients with CrC versus controls. expression levels of the mirnas were normalized to 
rnU6B. (A) Let-7a is significantly downregulated in patient samples compared to normal ones (P-value = 0.02); (B) Let-7f is significantly downregulated in 
plasma samples of patients compared to normal group (P-value = 0.02). Data were analyzed using mann–Whitney test. Graphs represent the mean value 
and standard error of mean of each group.
Figure 3. stool let-7a-5p and let-7f-5p expression level in 51 patients with CrC versus controls. expression levels of the mirnas were normalized to 
rnU6B. (A) Let-7a is significantly downregulated in stool samples of patients compared with the normal group (P-value = 0.03); (B) Let-7f is significantly 
downregulated in samples of patients in comparison with the normal group (P-value = 0.003). Data were analyzed using mann–Whitney test. Graphs 
represent the mean value and standard error of mean of each group.
Validation of miRNA expression differences by qRT-
PCR. Two miRNAs (let-7a-5p and let-7f-5p) out of the seven 
differentially expressed miRNAs in both plasma and stool of 
patients with CRC by microarray analysis were validated by 
qRT-PCR on plasma and stool samples of 51 patients with 
CRC and 26 healthy subjects. We observed significantly lower 
expression by Mann–Whitney test of let-7a-5p (P = 0.02) and 
let-7f-5p (P = 0.02) in plasma samples of patients with CRC 
and of let-7a-5p (P = 0.03) and let-7f-5p (P = 0.003) in stool 
samples of patients with CRC compared with that of the 
normal group samples, confirming the results obtained with 
microarray analysis (Figs. 2 and 3). There was no correlation 
between let-7a or let-7f expression and cancer stage or tumor 
site in patients with CRC.
Evaluation of specificity and sensitivity of the let-7 
miRNAs. Receiver operating characteristic (ROC) curve 
analyses were performed on plasma and fecal let-7a-5p and let-
7f-5p separately. The ROC curve analysis demonstrated that 
let-7f-5p expression level in the stool samples has a significant 
specificity and sensitivity to discriminate patients with CRC 
from normal individuals. The area under curve was 70.9% with 
a standard deviation error of 0.06 (P-value = 0.003; Fig. 4).
Discussion
To our knowledge, no study has been done on simultaneous 
evaluation of miRNA expression in both plasma and stool 
samples of patients with CRC to date. In this study, for the 
first time, we investigated simultaneously the plasma and 
stool miRNA expression in patients with early stages (I, II) 
of CRC and in neoplasm-free individuals as controls. We 
believed that aberrant expression of specific miRNAs on 
these types of samples might help to identify potential CRC 
biomarkers.
When expression profiles of miRNA from plasma and 
stool samples of the patients with CRC were compared 
with those of the healthy subjects, 80 and 150 differentially 
expressed miRNAs, respectively, were detected. From the 
differentially expressed miRNAs, only seven were seen in 
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both plasma and stool samples. With regard to cancer, let-
7a-5p and let-7f-5p were the most intriguing from those seven 
miRNAs, and we wanted to confirm their downregulation 
in a bigger cohort of patients by qRT-PCR. Our validation 
study agreed with the results from microarrays; expression 
levels of the let-7a-5p and let-7f-5p miRNAs were signifi-
cantly decreased in both plasma and stool samples of patients 
with early stages of CRC compared with those of healthy 
subjects. Moreover, ROC curve analysis demonstrated that 
fecal let-7f expression levels have significant sensitivity and 
specificity to distinguish between patients with CRC and 
healthy subjects.
Reduced expression of let-7 family members has been 
reported in many tumors.24–28 For example, lower expression 
of let-7f has been reported as a marker for early stage ovarian 
cancer detection.29 Moreover, there are numerous reports that 
indicate that this miRNA family is differentially expressed 
in CRC.22,30–33 However, there is very little information of 
downregulation of the let-7 miRNA family members in CRC 
plasma or stool samples. Wang et al performed miRNA pro-
filing on two pooled plasma samples of 10 patients with CRC 
and 10 normal controls targeting 742 miRNAs by qRT-PCR.13 
Interestingly, let-7a miRNA was downregulated, among oth-
ers, with a fold change 5.
It is well known that let-7a and let-7f miRNAs are located 
at chromosome 9q22.3, forming a cluster along with let-7d 
miRNA. However, the mechanisms of action of these let-7 fam-
ily members on mRNA are not fully understood, even though 
some of their targets are known. Experimentally verified let-7a 
target genes with strong evidence include some known  cancer 
genes, such as BCL2, CASP8, CCND2, DICER1, EWSR1, 
FOXA1, HMGA1, HMGA2, HRAS, KRAS, MYC, MPL, 
NF2, NRAS, and PRDM1 (according to the databases miR-
TarBase34 and COSMIC,35 accessed on September 10, 2015). 
Experimentally verified let-7f-5p target cancer genes include 
CCND1, MYC, MPL, NKX2-1, and PRDM1 (according to 
the same databases). However, it is important to note that all 
the let-7 variants share an identical seed sequence that is critical 
for target recognition.36 These target genes of let-7 miRNAs 
are involved in carcinogenesis regulating directly or indirectly 
cell cycle, apoptosis, and cell adhesion. For example, reduced 
expression of let-7 is related to cell proliferation and oncogenic 
transformation by increasing expression of HMGA2.37,38 
Moreover, restoring let-7 levels in pancreatic cancer-derived 
cell lines strongly inhibits cell proliferation.24 More specifically 
with regard to let-7a and let-7f, several studies have connected 
these miRNAs with oncogenesis and/or cell growth. Let-7f 
has been reported to modulate β-catenin/Wnt signaling that is 
related to growth and development of stem cells via its binding 
to Axin 2 and subsequent degradation of β-catenin in human 
mesenchymal stem cells.39 It has been also reported that the 
miRNA let-7a can revert cell growth in lymphoma and in lung 
cancer.40,41 In addition, let-7a plays a role in STAT3 signal-
ing at least in cervical carcinogenesis.42 Interestingly, regarding 
CRC, previous results have shown that transfection of let-7a-1 
precursor miRNA to human colon cancer cells resulted in 
lower levels of RAS and c-myc proteins and subsequent sig-
nificant growth suppression.33
It is important to note that hsa-miR-21-5p was downregu-
lated in both plasma and stool of patients with CRC compared 
with that of healthy subjects after the microarray analysis. Sur-
prisingly, this miRNA is upregulated in patients with CRC, 
even in their serum, according to previous  studies.43 However, 
it has been associated with metastasis and poor  survival, and 
our patients with CRC were all in early and curable stage. It 
seems that miR-21 has significant potential as a prognostic 
marker, rather than as an early detection marker.43
Our validation study results confirmed that the expression 
level of the let-7a-5p and let-7f-5p was significantly decreased 
in both plasma and stool samples of patients with stages I and 
II CRC compared with those of healthy subjects. Moreover, 
ROC curve analysis demonstrated that fecal let-7f-5p expres-
sion levels have significant sensitivity and specificity to distin-
guish between patients with CRC and healthy subjects. We 
suggest that the downregulation of fecal let-7f-5p in patients 
with CRC may be useful in early diagnosis of this cancer. Nev-
ertheless, further studies on larger series of patients, especially 
with different stages of CRC, adenoma, and other precancer-
ous lesions, are needed to clarify whether these miRNAs have 
the potential to be used for early detection of CRC.
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Figure 4. area under curve (aUC) of receiver operating characteristic 
(roC) analysis for let-7f relative expression in fecal samples. roC curve 
analysis revealed that fecal let-7f relative expression has significant 
specificity and sensitivity to distinguish between patients with CRC and 
normal individuals. The aUC value is 70.9% with the standard error of 
0.06 (P-value = 0.003).
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STOOL PLASMA
miRNA P-VALUE Q-VALUE miRNA P-VALUE Q-VALUE
UP hsa-mir-4642 0.004 0.1 hsa-mir-32-3p 0.011 0.07
hsa-mir-617 0.042 0.1 hsa-mir-4455 0.020 0.09
DoWn hsa-mir-3124-5p 9.47e-06 0.004 hsa-mir-222-3p 8.39e-05 0.01
hsa-mir-124-3p 8.73e-05 0.016 hsa-mir-186-5p 1.72e-04 0.01
hsa-mir-6511b-5p 2.95e-04 0.034 hsa-mir-744-5p 1.82e-04 0.01
hsa-mir-320a 3.61e-04 0.034 hsa-mir-4291 4.41e-04 0.02
hsa-mir-4430 5.91e-04 0.036 hsa-mir-513a-5p 8.44e-04 0.03
hsa-mir-4478 5.95e-04 0.036 hsa-let-7f-1-3p 9.99e-04 0.03
hsa-mir-5008-5p 7.13e-04 0.036 hsa-mir-425-3p 0.001 0.03
hsa-mir-4648 7.80e-04 0.036 hsa-mir-98-5p 0.002 0.04
hsa-mir-1236-5p 9.74e-04 0.040 hsa-mir-432-5p 0.002 0.04
hsa-mir-4259 0.002 0.069 hsa-mir-1304-3p 0.002 0.04
hsa-mir-3185 0.002 0.080 hsa-mir-4299 0.002 0.04
hsa-mir-1233-1-5p 0.003 0.080 hsa-mir-363-3p 0.002 0.04
hsa-mir-4688 0.003 0.080 hsa-mir-142-5p 0.003 0.04
hsa-mir-4419b 0.005 0.1 hsa-mir-625-5p 0.004 0.05
hsa-mir-5088 0.005 0.1 hsa-mir-6508-5p 0.004 0.05
hsa-mir-3678-3p 0.005 0.1 hsa-mir-18a-5p 0.005 0.06
hsa-mir-1295b-3p 0.005 0.1 hsa-mir-29a-3p 0.005 0.06
hsa-mir-518c-5p 0.006 0.1 hsa-mir-23b-3p 0.005 0.06
hsa-mir-4776-5p 0.007 0.1 hsa-mir-26a-5p 0.005 0.06
hsa-mir-663a 0.007 0.1 hsa-mir-181b-5p 0.006 0.06
hsa-mir-526b-5p 0.008 0.1 hsa-mir-148a-3p 0.007 0.06
hsa-mir-514b-5p 0.009 0.1 hsa-mir-29c-3p 0.008 0.07
hsa-mir-1183 0.009 0.1 hsa-mir-654-5p 0.008 0.07
hsa-mir-765 0.009 0.1 hsa-mir-26b-5p 0.008 0.07
hsa-mir-3944-3p 0.010 0.10 hsa-let-7d-5p 0.008 0.07
hsa-mir-1247-3p 0.011 0.1 hsa-mir-27b-3p 0.009 0.07
hsa-mir-4496 0.011 0.1 hsa-mir-5580-3p 0.009 0.07
hsa-mir-3158-5p 0.012 0.1 hsa-mir-451a 0.010 0.07
hsa-mir-3926 0.012 0.1 hsa-mir-142-3p 0.010 0.07
hsa-mir-4532 0.012 0.1 hsa-mir-4728-5p 0.010 0.07
hsa-mir-1229-5p 0.013 0.1 hsa-mir-19a-3p 0.011 0.07
hsa-mir-494 0.014 0.1 hsa-mir-629-5p 0.011 0.07
hsa-mir-3911 0.014 0.1 hsa-mir-103a-3p 0.012 0.07
hsa-mir-3605-5p 0.014 0.1 hsa-mir-15a-5p 0.013 0.07
hsa-mir-3648 0.015 0.1 hsa-mir-331-3p 0.013 0.07
hsa-mir-4444 0.015 0.1 hsa-mir-933 0.014 0.07
hsa-let-7f-5p 0.015 0.1 hsa-mir-140-3p 0.016 0.09
hsa-mir-4793-5p 0.016 0.1 hsa-mir-106b-5p 0.017 0.09
hsa-mir-4667-5p 0.016 0.1 hsa-mir-107 0.018 0.09
hsa-mir-3130-3p 0.016 0.1 hsa-mir-4323 0.018 0.09
hsa-mir-1203 0.017 0.1 hsa-mir-151a-5p 0.019 0.09
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STOOL PLASMA
miRNA P-VALUE Q-VALUE miRNA P-VALUE Q-VALUE
hsa-mir-4515 0.017 0.1 hsa-mir-652-3p 0.020 0.09
hsa-mir-4486 0.018 0.1 hsa-mir-409-3p 0.020 0.09
hsa-mir-877-5p 0.018 0.1 hsa-let-7f-5p 0.021 0.09
hsa-mir-4451 0.018 0.1 hsa-mir-20b-5p 0.023 0.09
hsa-mir-631 0.018 0.1 hsa-mir-378i 0.023 0.09
hsa-mir-5190 0.018 0.1 hsa-mir-16-5p 0.023 0.09
hsa-mir-874 0.019 0.1 hsa-mir-199a-3p 0.023 0.09
hsa-mir-4271 0.019 0.1 hsa-mir-27a-3p 0.026 0.10
hsa-mir-1260a 0.019 0.1 hsa-mir-148b-3p 0.027 0.10
hsa-mir-192-5p 0.019 0.1 hsa-mir-1236-5p 0.027 0.10
hsa-mir-141-3p 0.020 0.1 hsa-let-7b-3p 0.028 0.10
hsa-mir-601 0.020 0.1 hsa-mir-223-3p 0.028 0.10
hsa-mir-3680-3p 0.020 0.1 hsa-mir-423-3p 0.029 0.10
hsa-mir-4419a 0.021 0.1 hsa-mir-663a 0.029 0.10
hsa-mir-4746-3p 0.021 0.1 hsa-let-7a-5p 0.029 0.10
hsa-mir-3676-5p 0.021 0.1 hsa-mir-122-5p 0.030 0.10
hsa-mir-640 0.022 0.1 hsa-mir-221-3p 0.031 0.10
hsa-mir-4778-5p 0.022 0.1 hsa-let-7c 0.031 0.102
hsa-mir-3202 0.022 0.1 hsa-mir-671-3p 0.033 0.10
hsa-mir-3135b 0.022 0.1 hsa-mir-130b-3p 0.033 0.10
hsa-mir-4634 0.023 0.1 hsa-mir-151b 0.034 0.10
hsa-mir-33a-3p 0.023 0.1 hsa-mir-30b-5p 0.034 0.10
hsa-mir-4429 0.023 0.1 hsa-mir-15b-5p 0.034 0.10
hsa-mir-483-5p 0.023 0.1 hsa-mir-185-5p 0.036 0.10
hsa-mir-4640-3p 0.023 0.1 hsa-mir-23a-3p 0.036 0.10
hsa-mir-4465 0.023 0.1 hsa-mir-150-5p 0.037 0.10
hsa-mir-3200-5p 0.024 0.1 hsa-mir-146a-5p 0.038 0.10
hsa-mir-5188 0.024 0.1 hsa-let-7g-5p 0.038 0.10
hsa-mir-4713-3p 0.024 0.1 hsa-mir-25-3p 0.038 0.10
hsa-mir-4728-5p 0.024 0.1 hsa-mir-342-3p 0.038 0.10
hsa-mir-378i 0.024 0.1 hsa-mir-125a-5p 0.039 0.10
hsa-mir-193a-5p 0.024 0.1 hsa-mir-21-5p 0.043 0.11
hsa-mir-3667-5p 0.025 0.1 hsa-mir-130a-3p 0.044 0.11
hsa-mir-3917 0.025 0.1 hsa-mir-4313 0.045 0.12
hsa-mir-200a-3p 0.025 0.1 hsa-mir-361-5p 0.046 0.12
hsa-mir-302c-5p 0.025 0.1 hsa-let-7b-5p 0.047 0.12
hsa-mir-6133 0.025 0.1 hsa-mir-6073 0.048 0.12
hsa-mir-5189 0.026 0.1
hsa-mir-4660 0.027 0.1
hsa-mir-3935 0.027 0.1
hsa-mir-4428 0.028 0.1
hsa-mir-4665-5p 0.028 0.1
hsa-mir-3934-5p 0.029 0.1
hsa-mir-550a-5p 0.030 0.1
hsa-mir-760 0.030 0.1
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miRNA P-VALUE Q-VALUE miRNA P-VALUE Q-VALUE
hsa-mir-21-5p 0.031 0.1
hsa-let-7a-5p 0.031 0.1
hsa-mir-5006-5p 0.031 0.1
hsa-mir-5001-5p 0.031 0.1
hsa-mir-622 0.031 0.1
hsa-mir-3180-5p 0.032 0.1
hsa-mir-4454 0.032 0.1
hsa-mir-378a-3p 0.032 0.1
hsa-mir-6126 0.032 0.1
hsa-mir-766-3p 0.033 0.1
hsa-mir-371a-5p 0.033 0.1
hsa-mir-3622a-5p 0.033 0.1
hsa-mir-5739 0.034 0.1
hsa-mir-4261 0.034 0.1
hsa-mir-200b-3p 0.034 0.1
hsa-mir-4664-3p 0.034 0.1
hsa-mir-200b-3p 0.034 0.1
hsa-mir-4664-3p 0.034 0.1
hsa-mir-200b-3p 0.034 0.1
hsa-mir-4664-3p 0.034 0.1
hsa-mir-200b-3p 0.034 0.1
hsa-mir-4664-3p 0.034 0.1
hsa-mir-1202 0.035 0.1
hsa-mir-4298 0.035 0.1
hsa-mir-4513 0.035 0.1
hsa-mir-3682-3p 0.035 0.1
hsa-mir-1182 0.036 0.1
hsa-mir-215 0.036 0.1
hsa-mir-193b-5p 0.037 0.1
hsa-mir-718 0.037 0.1
hsa-mir-4743-5p 0.037 0.1
hsa-mir-623 0.037 0.1
hsa-mir-6717-5p 0.037 0.1
hsa-mir-652-5p 0.037 0.1
hsa-mir-320d 0.037 0.1
hsa-mir-6510-5p 0.039 0.1
hsa-mir-1226-5p 0.039 0.1
hsa-mir-583 0.040 0.1
hsa-mir-4459 0.040 0.1
hsa-mir-575 0.040 0.1
hsa-mir-3141 0.040 0.1
hsa-mir-3174 0.040 0.1
hsa-mir-602 0.041 0.1
hsa-mir-6086 0.041 0.1
hsa-mir-4485 0.042 0.1
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miRNA P-VALUE Q-VALUE miRNA P-VALUE Q-VALUE
hsa-mir-6718-5p 0.042 0.1
hsa-mir-4470 0.042 0.1
hsa-mir-4738-3p 0.042 0.1
hsa-mir-4721 0.042 0.1
hsa-mir-3188 0.043 0.1
hsa-mir-211-3p 0.044 0.1
hsa-mir-4672 0.044 0.1
hsa-mir-936 0.044 0.1
hsa-mir-194-5p 0.044 0.1
hsa-mir-487b 0.045 0.1
hsa-mir-6505-5p 0.046 0.1
hsa-mir-4669 0.047 0.1
hsa-mir-345-5p 0.047 0.1
hsa-mir-150-3p 0.047 0.1
hsa-mir-3173-3p 0.048 0.1
hsa-mir-125a-3p 0.048 0.1
hsa-mir-3147 0.048 0.1
hsa-mir-4690-5p 0.048 0.1
hsa-mir-22-3p 0.048 0.1
hsa-mir-1185-1-3p 0.049 0.1
hsa-mir-1287 0.049 0.1
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